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Abstract
Both the new generation of antipsychotics and the more traditional antipsychotic drugs produce
an important and meaningful improvement in patients with schizophrenia, but most patients are
neither cured nor free of symptoms. As a consequence, it is common to switch from one drug to
another in the hope of obtaining a better response. All antipsychotic drugs produce some side
effects, so switching can also be a tolerance issue. There are reports in the literature on the tactics
of switching: abrupt discontinuation, cross tapering, starting a patient on a new drug while
continuing with the old drug until the new drug has reached a steady state, or some variation on
these tactics. In this issue, Ganguli et al. have carried out a randomized switching study, the data
from which indicates the tactics that might be optimal. We put this paper into context, provide a
critique and describe indications for switching.
Background
Ganguli et al. [1] studied the strategy of switching patients
from olanzapine to risperidone. They found that slow
tapering of the initial antipsychotic after the new drug had
been titrated to the full dose produces fewer problems
during the switch than abrupt discontinuation or gradual
discontinuation before starting a new drug.
The abrupt discontinuation of clozapine does produce an
acute worsening of psychosis in some patients and side
effects as a result of withdrawal [2]. It is possible that some
withdrawal side effects arise from the discontinuation of
antipsychotic drugs and/or the antiparkinsonian drugs
(often co-administered to reduce extrapyramidal side
effects). It is less clear whether this occurs with other
antipsychotic drugs [2]. Olanzapine has many pharmaco-
logical similarities to clozapine, so it is plausible that such
phenomena could occur. Problems that might occur on
switching include rebound worsening of psychotic symp-
toms, side effects, such as the addition of side effects of the
old and new drugs, or side effects specific to the new drug,
or differences in efficacy between the drugs. Problems
might be specific to the discontinuation of the drug or to
the drug to which the patient is switched. This strategy
(sometimes called 'overlap and taper') ensures that the
patient is covered with an adequate plasma level of the
added drug before the former drug is discontinued. An
increase in side effects did not occur in the Ganguli et al.
study [1] or in other studies [3-8]. Such a strategy would
not apply to all drugs where the side effects of each of the
drugs could combine to produce a significant increase in
side effects.
Discussion
Knowing the tactics of switching advances the practical
use of these drugs and advances the field. We have good
basic information on efficacy, safety and pharmacokinet-
ics from registrational studies. However, there is little
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information on many of the practical and strategic issues
of drug administration [9]. Ganguli et al.'s study is one
step towards remedying the situation. We would distin-
guish this study, which makes a clear-cut contribution,
from many of the post-marketing studies supported by
the pharmaceutical industry, which merely replicate effi-
cacy and safety studies that have been performed many
times before. The endless replication of similar studies
does not add much information, but studies directed at
filling in the gaps in our knowledge do. In our opinion,
some of the promotional material exaggerates the possi-
bilities of withdrawal effects.
Role of open studies
Studies on the switch process are also carried out in part
for marketing purposes to show that there is improvement
on the new drug. We have shown that open studies sys-
tematically produce more positive results favoring the
sponsor and are pertinent to the evaluation of such stud-
ies. This said, such open studies are valuable: it is harder
to recruit patients (or to recruit physicians to manage
patients) in double-blind studies than in open studies.
Some relaxation of the controls against bias is traded off
against the lower costs and more representative samples
of patients. Some flexibility in the design of studies on the
tactics of using drugs will result in a wider range of studies
being carried out at an affordable cost.
Weight gain: the most common reason to switch
The most common reason for switching from olanzapine
is excessive weight gain. Antipsychotic drugs differ in their
propensity to cause weight gain: olanzapine and clozap-
ine cause the most; quetiapine and risperidone cause
some; ziprasidone, aripiprazole, amisulpride and
haloperidol cause little or no weight gain. There are wide
individual differences among patients on a given drug:
some patients gain substantial weight, others gain little,
some gain none and some lose weight. The time course of
weight gain is fairly rapid in the first few weeks, but slows
down and seems to plateau after several months. Young
patients (that is, children, adolescents and young adults)
are much more liable to gain a substantial amount of
weight. The rank ordering of antipsychotic weight gain
propensity is similar in younger patients; however, even
haloperidol causes substantial weight gain among young
patients. Patients who had previously been on a high
weight-gaining antipsychotic are much less liable to gain
more than those who were not. It is important, therefore,
to weigh patients approximately every week in the first few
months of their treatment and then less frequently after-
wards. Substantial weight gain is associated with type-2
diabetes and, for some patients, the consequences of
obesity must be regarded as a serious medical event. If it is
apparent that a given patient is likely to gain a lot of
weight, the clinician is faced with limiting weight gain by
diet, exercise, a pharmacological intervention or by
switching to another drug, which causes less weight gain.
As most of the weight gain occurs early on, the switch or
other coping strategies should be made as soon as possi-
ble. Therefore, the problem of weight gain should be faced
in the first 3 to 6 weeks of drug treatment and a strategy
(diet, exercise, a concomitant drug, which might reduce
weight gain, or switching antipsychotics) should be
devised to limit the weight gain rather than wait until the
patient has already gained weight when it is hard to lose.
To switch or not to switch
Although antipsychotic administration produces consid-
erable benefits in schizophrenic patients, these drugs do
not produce a complete or permanent cure. Many residual
symptoms remain and continued drug use is required,
essentially for life, to prevent relapse. Since patients do
have residual symptoms, there is hope that a better
response could be achieved with a different drug. Conse-
quently, switching or the addition of other augmenting
drugs occurs frequently. The various antipsychotics differ
in efficacy, side-effect profiles and cost. Not every patient
has every side effect. It is likely that one could find, by trial
and error, a drug with a better side-effect profile for an
individual patient. There is evidence from controlled trials
that patients who do not tolerate or like a given drug will
neither like nor tolerate that drug when randomized in a
double-blind randomized-assignment trial [10]. It is not
known whether there are individual differences such that
one patient will respond to drug A and not drug B;
another to drug B but not drug A. A past history of a
patient's experience with a given drug can be helpful in
the choice of drug. Thorough documentation of the dose,
side effects and therapeutic efficacy will facilitate changes
in medication in the future.
Conclusion
In general, there are few problems with switching from
one antipsychotic to another, but they do occur. In decid-
ing to switch, Ganguli et al.'s study suggests that maintain-
ing the full dose of the initial antipsychotic until the
second drug has been titrated to its full dose is the pre-
ferred strategy.
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